From The Bench To The Boardroom with ImmunityBio's Enrique Diloné

Business Of Biotech

We love to hear from our listeners. Send us a message.

While organic chemistry lectures caused many of his peers at NYU to wring their hands, gnash their teeth, and question life choices, then-19-year-old Enrique Diloné ate those classes for lunch. They inspired him to earn a Seton Hall Ph.D. in chemistry, and to go to work as a big bio research scientist. Along the way, Dr. Diloné got bit by the biotech business bug. It wasn’t easy. A whole bunch of MBA and executive learning programs at Rutgers, MIT, and Harvard, and many years of experience later, he’s Chief Technology Officer at Immunity Bio, which he joined in advance of the company winning FDA approval of ANKTIVA, its IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer, in April '24. On this episode of the Business of Biotech, we follow Dr. Diloné’s path from the bench to the boardroom, and learn how valuable that rare bridge between CMC and the executive offices really is.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Capitole

1. Exploring Bioprocessing Innovations With Dr. DeLonay (00:00:00)

2. Career Transition in Biotech Industry (00:04:18)

3. Balancing Science and Business in Pharma (00:22:41)

4. Navigating Challenges in Biotech Industry (00:28:48)

5. Transitioning to Commercial Operations Success (00:38:57)

6. Managing Priorities in Biotech Industry (00:50:13)

7. Navigating International Business in Biotech (00:58:46)